High expression of MAGOH is closely associated with poor prognosis of gliomas

Background: MAGOH (Mago homolog, exon junction complex subunit) is a protein-coding gene，which mediates mRNA processing. Studies have shown that MAGOH promotes gastric cancer by activating the B-Raf/MEK/ERK signaling pathway. Furthermore, this gene is involved in the development of breast cancer and prostate cancer. Therefore, we hypothesized that MAGOH also affects the formation and development of gliomas. Methods: Sequential data filtering (survival analysis, independent prognostic analysis, ROC curve analysis, and clinical correlation analysis) was performed using information on gene expression and clinical data from the Chinese Glioma Genome Atlas (CGGA) microarray database. Then, bioinformatics analysis (Kaplan-Meier survival analysis, univariate Cox analysis, multivariate Cox analysis, and ROC curve analysis) using CGGA and The Cancer Genome Atlas (TCGA) microarray was used to analyze biological manifestation of MAGOH. Gene set enrichment analysis and immune infiltration analysis were performed for this gene. R language, Perl and GSEA software were used for statistical analysis and graphic processing. Results: Kaplan-Meier survival analysis, univariate Cox analysis, multivariate Cox analysis and ROC curve analysis showed that MAGOH was an independent prognostic indicator in glioma patients, and its up-regulation was closely associated with poor prognosis of glioma patients. In addition, enrichment analysis and immune infiltration analysis showed that the immune score and interstitial score were significantly related to the survival of glioma patients. Moreover, MAGOH was closely related to the immune infiltration and inflammatory response of glioma. Conclusion: MAGOH is an independent prognostic factor in glioma patients, especially in low-grade glioma patients. MAGOH may affect the survival of glioma patients by promoting the infiltration of B cells, but inhibiting infiltration of CD4+ T cells and CD8+ T cells and activating the cell metabolism of glioma. MAGOH may be an important biomarker for the treatment of glioma.